These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 11742876)

  • 21. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system.
    Liu XH; Kirschenbaum A; Yao S; Levine AC
    Endocrinology; 2005 Apr; 146(4):1991-8. PubMed ID: 15618359
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of osteoprotegerin and osteoprotegerin ligand on osteoclast formation by arthroplasty membrane derived macrophages.
    Itonaga I; Sabokbar A; Murray DW; Athanasou NA
    Ann Rheum Dis; 2000 Jan; 59(1):26-31. PubMed ID: 10627423
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones.
    Ikeda T; Utsuyama M; Hirokawa K
    J Bone Miner Res; 2001 Aug; 16(8):1416-25. PubMed ID: 11499864
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-beta oestradiol and raloxifene.
    Cheung J; Mak YT; Papaioannou S; Evans BA; Fogelman I; Hampson G
    J Endocrinol; 2003 Jun; 177(3):423-33. PubMed ID: 12773123
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption.
    Kostenuik PJ; Shalhoub V
    Curr Pharm Des; 2001 May; 7(8):613-35. PubMed ID: 11375772
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis of osteoprotegerin and RANKL by megakaryocytes is modulated by oestrogen.
    Bord S; Frith E; Ireland DC; Scott MA; Craig JI; Compston JE
    Br J Haematol; 2004 Jul; 126(2):244-51. PubMed ID: 15238146
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential expression of RANKL and osteoprotegerin in gingival crevicular fluid of patients with periodontitis.
    Mogi M; Otogoto J; Ota N; Togari A
    J Dent Res; 2004 Feb; 83(2):166-9. PubMed ID: 14742657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunohistochemical localization of receptor activator of nuclear factor kappaB (RANK) and its ligand (RANKL) in human deciduous teeth.
    Lossdörfer S; Götz W; Jäger A
    Calcif Tissue Int; 2002 Jul; 71(1):45-52. PubMed ID: 12043011
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chronology and regulation of gene expression of RANKL in the rat dental follicle.
    Liu D; Yao S; Pan F; Wise GE
    Eur J Oral Sci; 2005 Oct; 113(5):404-9. PubMed ID: 16202028
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Calcium deposition and expression of bone modelling markers in the tympanic membrane following acute otitis media.
    Raustyte G; Cayé-Thomasen P; Hermansson A; Andersen H; Thomsen J
    Int J Pediatr Otorhinolaryngol; 2006 Mar; 70(3):529-39. PubMed ID: 16159670
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts.
    Takami M; Takahashi N; Udagawa N; Miyaura C; Suda K; Woo JT; Martin TJ; Nagai K; Suda T
    Endocrinology; 2000 Dec; 141(12):4711-9. PubMed ID: 11108286
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand.
    Kong YY; Feige U; Sarosi I; Bolon B; Tafuri A; Morony S; Capparelli C; Li J; Elliott R; McCabe S; Wong T; Campagnuolo G; Moran E; Bogoch ER; Van G; Nguyen LT; Ohashi PS; Lacey DL; Fish E; Boyle WJ; Penninger JM
    Nature; 1999 Nov; 402(6759):304-9. PubMed ID: 10580503
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors.
    Itoh K; Udagawa N; Matsuzaki K; Takami M; Amano H; Shinki T; Ueno Y; Takahashi N; Suda T
    J Bone Miner Res; 2000 Sep; 15(9):1766-75. PubMed ID: 10976996
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of the osteoprotegerin/receptor activator of nuclear factor-kappa B ligand system in gingival crevicular fluid and tissue of patients with chronic periodontitis.
    Lu HK; Chen YL; Chang HC; Li CL; Kuo MY
    J Periodontal Res; 2006 Aug; 41(4):354-60. PubMed ID: 16827732
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The effects of 17 beta-estradiol on the expression of osteoprotegerin, the ligand of osteoprotegerin and related cytokines in osteosarcoma MG63 cells].
    Su X; Liao EY; Peng J; Wu XP
    Zhonghua Nei Ke Za Zhi; 2003 Nov; 42(11):800-3. PubMed ID: 14636471
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral squamous cell carcinoma cells induce osteoclast differentiation by suppression of osteoprotegerin expression in osteoblasts.
    Tada T; Jimi E; Okamoto M; Ozeki S; Okabe K
    Int J Cancer; 2005 Aug; 116(2):253-62. PubMed ID: 15800904
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
    Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
    J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Osteoclast induction in periodontal tissue during experimental movement of incisors in osteoprotegerin-deficient mice.
    Oshiro T; Shiotani A; Shibasaki Y; Sasaki T
    Anat Rec; 2002 Apr; 266(4):218-25. PubMed ID: 11920384
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Using the ratio of serum osteoprotegerin ligand to osteoprotegerin to evaluate renal osteodystrophy in dialysis patients.
    Grzegorzewska AE; Mlot M
    Adv Perit Dial; 2005; 21():188-93. PubMed ID: 16686316
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma.
    Terpos E; Politou M; Szydlo R; Nadal E; Avery S; Olavarria E; Kanfer E; Goldman JM; Apperley JF; Rahemtulla A
    Leukemia; 2004 Aug; 18(8):1420-6. PubMed ID: 15215875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.